| 國立成功大學 |
2023 |
Prospective, open-label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE study
|
Yang, T.-S.;Chen, H.-H.;Bo-Wen, L.;Kim, T.W.;Kim, J.G.;Ahn, J.B.;Lee, M.-A.;Lin, J.;Ho, G.F.;Anh, L.T.;Temraz, S.;Burge, M.;Chua, Chua C.;Huang, J.;Park, Y.S. |
| 臺大學術典藏 |
2022-09-15T01:08:51Z |
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
|
Chia-Chi Lin; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; Hsu C. |
| 臺大學術典藏 |
2022-08-19T00:20:57Z |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
Cheng A.-L.; Meng R.; Chao Y.; Hsieh T.-Y.; Huang W.-T.; Hwang W.-S.; Yu C.-W.; Hsieh R.-K.; Huo T.-I.; Yang T.-S.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:31Z |
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
|
Lin C.-C.; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-12T06:28:05Z |
Long-Term Survival of HLA-DR15+ Pig Skin in SCID Mice After Reconstitution With Human Peripheral Blood Mononuclear Cells and Under Short-Term Immunosuppression
|
Tai H.-C.; Tu C.-F.; Lee J.-M.; Ho L.-L.; Tseng Y.-L.; Chou N.-K.; Yang T.-S.; Weng C.-N.; Lee P.-H.; KING-JEN CHANG; Tang Y.-B. |
| 臺大學術典藏 |
2022-06-10T06:11:12Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; ZHONG-ZHE LIN; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2022-05-13T08:04:23Z |
Healthcare-associated infections in intensive care units in Taiwan, South Korea, and Japan: Recent trends based on national surveillance reports
|
Chiang C.-H.; Pan S.-C.; Yang T.-S.; Matsuda K.; Kim H.B.; Choi Y.H.; Hori S.; JANN-TAY WANG; Sheng W.-H.; Chen Y.-C.; Chang F.-Y.; Chang S.-C. |
| 國立成功大學 |
2022 |
Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety
|
Shao, Y.-Y.;Feng, Y.-H.;Yen, C.-J.;Yang, T.-S.;Shen, Y.-C.;Chao, Y.;Chen, J.-S.;Su, C.-Y.;Chen, W.-J.;Hsiang, Hsiang H.-L.;Hsu, C.-H. |
| 臺大學術典藏 |
2021-09-15T01:20:51Z |
Quantitative Proteomics of Th-MYCN Transgenic Mice Reveals Aurora Kinase Inhibitor Altered Metabolic Pathways and Enhanced ACADM to Suppress Neuroblastoma Progression
|
Hsieh C.-H.; Cheung C.H.Y.; Liu Y.-L.; Hou C.-L.; CHIA-LANG HSU; Huang C.-T.; Yang T.-S.; Chen S.-F.; Chen C.-N.; Hsu W.-M.; Huang H.-C.; Juan H.-F. |
| 臺大學術典藏 |
2021-09-01T01:54:24Z |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
|
ANN-LII CHENG; Kang Y.-K.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Luo R.; Feng J.; Ye S.; Yang T.-S.; Xu J.; Sun Y.; Liang H.; Liu J.; Wang J.; Tak W.Y.; Pan H.; Burock K.; Zou J.; Voliotis D.; Guan Z. |
| 臺大學術典藏 |
2021-09-01T01:54:16Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:01Z |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
Hsu C.; Yang T.-S.; Huo T.-I.; Hsieh R.-K.; Yu C.-W.; Hwang W.-S.; Hsieh T.-Y.; Huang W.-T.; Chao Y.; Meng R.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:59Z |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial
|
ANN-LII CHENG; Guan Z.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Yang T.-S.; Tak W.Y.; Pan H.; Yu S.; Xu J.; Fang F.; Zou J.; Lentini G.; Voliotis D.; Kang Y.-K. |
| 臺大學術典藏 |
2021-09-01T01:53:47Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:46Z |
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
|
ANN-LII CHENG; Thongprasert S.; Lim H.Y.; Sukeepaisarnjaroen W.; Yang T.-S.; Wu C.-C.; Chao Y.; Chan S.L.; Kudo M.; Ikeda M.; Kang Y.-K.; Pan H.; Numata K.; Han G.; Balsara B.; Zhang Y.; Rodriguez A.-M.; Zhang Y.; Wang Y.; Poon R.T.P. |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
|
ANN-LII CHENG; Cornelio G.; Shen L.; Price T.; Yang T.-S.; Chung I.J.; Dai G.-H.; Lin J.-K.; Sharma A.; Yeh K.-H.; Ma B.; Zaatar A.; Guan Z.; Masood N.; Srimuninnimit V.; Yau T.; Gibbs P.; Wang X.; Doval D.C.; Oh S.-T.; Shim B.Y.; Gorospe C.; Wang H.-M.; Sirachainan E.; Hill A.; Suh K.W.; Beier F.; Chatterjee S.; Lim R. |
| 臺大學術典藏 |
2021-08-11T03:46:49Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; ZHONG-ZHE LIN; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:46Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; PEI-JER CHEN; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:41Z |
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients
|
Yang T.-S.; Lu S.-N.; Chao Y.; Sheen I.-S.; Lin C.-C.; Wang T.-E.; Chen S.-C.; Wang J.-H.; Liao L.-Y.; Thomson J.A.; Wang-Peng J.; PEI-JER CHEN; Chen L.-T. |
| 臺大學術典藏 |
2021-05-26T02:46:23Z |
Scaffold derived from GGTA1 and CMAH double knockout pigs elicits only slight inflammation in a gene-edited pig model
|
Yen C.-H.;Hao-Chih Tai;Peng S.-H.;Yang T.-S.;Tu C.-F.; Yen C.-H.; HAO-CHIH TAI; Peng S.-H.; Yang T.-S.; Tu C.-F. |
| 臺大學術典藏 |
2021-05-06T01:51:53Z |
Healthcare-associated infections in intensive care units in Taiwan, South Korea, and Japan: Recent trends based on national surveillance reports
|
Chiang C.-H.; Pan S.-C.; Yang T.-S.; Matsuda K.; Kim H.B.; Choi Y.H.; Hori S.; Wang J.-T.; Sheng W.-H.; YEE-CHUN CHEN; Chang F.-Y.; Chang S.-C. |
| 臺大學術典藏 |
2021-03-18T02:02:48Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.;Kang Y.K.;Yang T.-S.;Chia-Tung Shun;Shao Y.-Y.;Su W.-C.;Sandoval-Tan J.;Chiou T.-J.;Jin K.;Hsu C.;Cheng A.-L.; Hsu C.-H.; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-10T08:56:00Z |
Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis
|
Hwang J.S.;Tu S.T.;Yang T.S.;Chen J.F.;Wang C.J.;Keh-Sung Tsai; Hwang J.S.; Tu S.T.; Yang T.S.; Chen J.F.; Wang C.J.; KEH-SUNG TSAI |
| 臺大學術典藏 |
2021-03-10T08:55:57Z |
The effects of strontium ranelate in Asian women with postmenopausal osteoporosis
|
Hwang J.S.;Chen J.F.;Yang T.S.;Wu D.J.;Keh-Sung Tsai;Ho C.;Wu C.H.;Su S.L.;Wang C.J.;Tu S.T.; Hwang J.S.; Chen J.F.; Yang T.S.; Wu D.J.; KEH-SUNG TSAI; Ho C.; Wu C.H.; Su S.L.; Wang C.J.; Tu S.T. |
| 臺大學術典藏 |
2021-03-10T08:55:54Z |
Erratum: The effects of strontium ranelate in Asian women with postmenopausal osteoporosis (Calcif Tissue Int (2008) 83:5 (308-314) DOI: 10.1007/s00223-008-9180-z)
|
Hwang J.S.; Chen J.F.; Yang T.S.; Wu D.J.; KEH-SUNG TSAI; Ho C.; Wu C.H.; Su S.L.; Wang C.J.; Tu S.T. |
